Compare iShares MSCI Australia ETF (EWA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Australia ETF trades at $28.55 (market cap $1.19B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 6.2× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is more actively traded (5,792,656 versus 1,624,631). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EWA | SYRE | |
|---|---|---|
Market Cap | $1.19B | $7.35B |
Volume | 5,792,656 | 1,624,631 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $108.92 |
52-Week Low | $24.95 | $22.18 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.77 with a modest 0.35% daily gain. Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. Recent news highlights institutional activity with Squarepoint Ops reducing its stake by 91.2% while Empowered Funds and Cetera Investment Advisers increased positions. Australian market sentiment is challenged by inflation concerns and oil price volatility affecting the commodity-driven economy.
The ETF faces headwinds from Australian economic pressures but offers exposure to commodity benefits. Upside potential exists with Seeking Alpha's $34.83 price target suggesting over 20% upside, though inflation and monetary policy risks persist. Institutional mixed positioning reflects uncertainty about Australia's economic trajectory amid global commodity fluctuations.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
